The Involvement of LAG-3[sup.positive] Plasma Cells in the Development of Multiple Myeloma

• Published in: International journal of molecular sciences 2023-12, Vol.25 (1)
• Main Authors: Kreiniz, Natalia, Eiza, Nasren, Tadmor, Tamar, Levy Yurkovski, Ilana, Matarasso Greenfeld, Sarah, Sabag, Adi, Mubariki, Raeda, Suriu, Celia, Votinov, Ekaterina, Toubi, Elias, Vadasz, Zahava
• Format: Article
• Language: English
• Subjects: Antibodies; B cells; Instrument industry; T cells; Viral antibodies
• ISSN: 1422-0067
• DOI: 10.3390/ijms25010549

The Lymphocyte-Activation Protein 3 (LAG-3) inhibitory receptor is expressed on regulatory plasma cells (PCs). Micro-environmental cells that express LAG-3 were found to be increased during the progression of smoldering multiple myeloma (SMM). To assess the possible role of LAG-3 expression on regulatory PCs in patients with plasma cell dyscrasia. Purified Cluster of Differentiation 138 (CD138[sup.+)] PCs from patients with premalignant conditions, active multiple myeloma (MM), and controls were analyzed for the expression of LAG-3 by flow cytometry. Autologous CD8[sup.+]T cells were incubated with sorted LAG-3[sup.pos] or LAG-3[sup.neg] PCs for 24 h. The expression of granzyme (Grz) in CD8[sup.+]T cells was assessed by flow cytometry. LAG-3 expression on PCs in active MM (newly diagnosed and relapse refractory MM) was significantly increased compared to monoclonal gammopathy of undetermined significance (MGUS)/ SMM. Grz expression was significantly decreased in CD8[sup.+]T cells incubated with CD138[sup.+]LAG-3[sup.pos] PCs, compared to CD138[sup.+]LAG-3[sup.neg] PCs in patients with plasma cell dyscrasia, n = 31, p = 0.0041. LAG-3 expression on malignant PCs can be involved in the development of MM from MGUS by decreasing the expression of Grz in CD8[sup.+]T cells.